COLORADO DENVER UNIVERSITY OF

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Phase 3

Completed

Conditions: ADPKD

Interventions: Drug: Sugar pill
Drug: Spironolactone

First Posted Date: 2013-05-15

Last Posted Date: 2019-08-20

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 61

Registration Number: NCT01853553

Locations: 🇺🇸
UColorado, Aurora, Colorado, United States

Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects

Phase 1

Terminated

Conditions: Schizophrenia

Interventions: Device: AVL-3288
Drug: Placebo

First Posted Date: 2013-05-10

Last Posted Date: 2016-12-30

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 12

Registration Number: NCT01851603

Locations: 🇺🇸
U of Colorado Denver, Aurora, Colorado, United States

Effects of Estrogen Deficiency on Energy Expenditure

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Estrogen suppression

First Posted Date: 2013-05-03

Last Posted Date: 2019-11-18

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 6

Registration Number: NCT01846728

Locations: 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel with Abiraterone Acetate
Drug: Cabazitaxel

First Posted Date: 2013-05-03

Last Posted Date: 2018-06-04

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 7

Registration Number: NCT01845792

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia in Remission

Interventions: Drug: PF-04449913

First Posted Date: 2013-04-26

Last Posted Date: 2022-01-25

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 31

Registration Number: NCT01841333

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis

Phase 4

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: IV methylprednisolone (steroids)
Drug: ACTHAR Gel (ACTH)

First Posted Date: 2013-04-23

Last Posted Date: 2023-04-27

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 37

Registration Number: NCT01838174

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States

Compassionate Use of Stiripentol in Dravet Syndrome

Conditions: Dravet Syndrome

First Posted Date: 2013-04-18

Last Posted Date: 2019-10-04

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT01835314

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

Phase 1

Terminated

Conditions: Schizophrenia

Interventions: Drug: Dronabinol
Other: Placebo Comparator

First Posted Date: 2013-04-16

Last Posted Date: 2015-09-21

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 13

Registration Number: NCT01832766

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Adiponectin and Ethnic Differences in Insulin Resistance

Completed

Conditions: Insulin Resistance
Type 2 Diabetes

Interventions: Other: none- observational study

First Posted Date: 2013-04-15

Last Posted Date: 2013-04-15

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 43

Registration Number: NCT01831102

Locations: 🇺🇸
University of Colorado Anschutz Medical Center, Aurora, Colorado, United States

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

Phase 2

Completed

Conditions: Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer

Interventions: Drug: Exemestane and tamoxifen
Drug: Exemestane

First Posted Date: 2013-04-15

Last Posted Date: 2022-03-03

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 36

Registration Number: NCT01831076

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy